Merck & Company, Inc. (new) (MRK): Price and Financial Metrics

Merck & Company, Inc. (new) (MRK)

Today's Latest Price: $83.54 USD

0.86 (1.04%)

Updated Aug 13 5:55pm

Add MRK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MRK Stock Summary

  • MRK has a market capitalization of $209,117,651,668 -- more than approximately 99.37% of US stocks.
  • MRK's went public 34.64 years ago, making it older than 92.9% of listed US stocks we're tracking.
  • In terms of volatility of its share price, MRK is more volatile than only 1.77% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Merck & Co Inc, a group of peers worth examining would be LLY, BIIB, MOSY, ICCC, and OIIM.
  • MRK's SEC filings can be seen here. And to visit Merck & Co Inc's official web site, go to
MRK Daily Price Range
MRK 52-Week Price Range

MRK Stock Price Chart Technical Analysis Charts

MRK Price/Volume Stats

Current price $83.54 52-week high $92.64
Prev. close $82.68 52-week low $65.25
Day low $82.01 Volume 7,113,849
Day high $83.63 Avg. volume 11,436,051
50-day MA $78.94 Dividend yield 2.95%
200-day MA $81.90 Market Cap 211.29B

Merck & Company, Inc. (new) (MRK) Company Bio

Merck & Company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. The company was founded in 1891 and is based in Kenilworth, New Jersey.

MRK Latest News Stream

Event/Time News Detail
Loading, please wait...

MRK Latest Social Stream

Loading social stream, please wait...

View Full MRK Social Stream

Latest MRK News From Around the Web

Below are the latest news stories about Merck & Co Inc that investors may wish to consider to help them evaluate MRK as an investment opportunity.

Merck & Co's Earnings Outlook

On Friday, July 31, Merck & Co (NYSE: MRK) will release its latest earnings report. Check out Benzinga's preview to understand the …

Benzinga | July 30, 2020

COVID-19 Impacts: Allergy Rhinitis Drugs Market will Accelerate at a CAGR of almost 4% through 2020-2024 | Increasing Prevalence Of Allergic Rhinitis to Boost Growth | Technavio

Technavio has been monitoring the allergy rhinitis drugs market and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire). Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact The market is fragmented, ...

Benzinga | July 29, 2020

The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Medpace Holdings Inc (NASDAQ: MEDP ) (saw an extension of its earnings-induced momentum) NeoGenomics, Inc. (NASDAQ: NEO )(reacted to its second-quarter results) OncoSec Medical Inc (NASDAQ: ONCS ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) Nkarta Inc (NASDAQ: NKTX ) Nurix Therapeutics Inc (NASDAQ: NRIX )(IPOed Friday) Verrica Pharmaceuticals Inc (NASDAQ:...

Benzinga | July 29, 2020

FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Breakthrough Therapy Designation to Merck’s MK-6482 for Certain Patients With Von Hippel-Lindau Disease-Associated RCC

Business Wire | July 29, 2020

DNA Script Expands Series B to $89M

PARIS & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--DNA Script today announced a $50 million extension to its Series B financing, bringing the total investment of this round to $89 million. This oversubscribed round is led by Casdin Capital and joined by Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, through its corporate venture arm, M Ventures — three of the world’s leaders in oligo synthesis — LSP, the Bpifrance Large Venture Fund and Illumina Ventures. Eli Casdin, Fo

Business Wire | July 29, 2020

Read More 'MRK' Stories Here

MRK Price Returns

1-mo 6.76%
3-mo 5.55%
6-mo 2.72%
1-year 3.18%
3-year 45.69%
5-year 64.40%
YTD -6.65%
2019 22.27%
2018 39.95%
2017 -1.49%
2016 15.05%
2015 -3.89%

MRK Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full MRK Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9577 seconds.